AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 979915 — intervention group
Group type: EXPERIMENTAL
Intervention: POMP (methotrexate, 6‐MP, vincristine, prednisone)
Number of subjects: 41
Study 979915 — intervention group
Group type: COMPARATOR
Intervention: COAP (cytosine arabinoside, cytoxan, vincristine, prednisone)
Number of subjects: 41
Study 979915 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 41
Study 979915 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to chemotherapy
Number of subjects: 41
Study 979915 — intervention group
Group type: COMPARATOR
Intervention: Both induction regimens
Number of subjects: 41
Study 30711603 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional method (C) - custom tray with impression compound and silicone
Number of subjects: 24
Study 30711603 — intervention group
Group type: COMPARATOR
Intervention: Simplified method (S) - stock tray with alginate
Number of subjects: 24
Study 29282108 — intervention group
Group type: EXPERIMENTAL
Intervention: E-bicycle with trailer for child transportation (3 months access)
Number of subjects: 36
Study 29282108 — intervention group
Group type: EXPERIMENTAL
Intervention: Longtail bicycle (3 months access)
Number of subjects: 36
Study 29282108 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular bicycle with trailer (3 months access)
Number of subjects: 36
Study 29282108 — intervention group
Group type: COMPARATOR
Intervention: Usual transportation and PA habits (control group)
Number of subjects: 36
Study 29282108 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (combined)
Number of subjects: 36
Study 24903002 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 16
Study 24903002 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (60 mg)
Number of subjects: 16
Study 24903002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22104255 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory‐muscle exercises for 10 min thrice a week for 4 wk
Number of subjects: 26
Study 22104255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 22104255 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory‐muscle exercises
Number of subjects: 26
Study 20216107 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 40
Study 20216107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18612060 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement intervention (performance feedback, peer‐to‐peer education, practice facilitator, IT support)
Number of subjects: 24
Study 18612060 — intervention group
Group type: COMPARATOR
Intervention: Performance feedback and benchmarking (control)
Number of subjects: 24
Study 15679714 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 4308
Study 12433007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 156
Study 12433007 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (sertraline)
Number of subjects: 156
Study 12433007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise and medication
Number of subjects: 156
Study 12433007 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 156
Study 11196124 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine
Number of subjects: 10
Study 11196124 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 7613099 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 16
Study 7613099 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 16
Study 7613099 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 75 mg/day
Number of subjects: 16
Study 7613099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10294790 — intervention group
Group type: COMPARATOR
Intervention: Standard message (control)
Number of subjects: 0
Study 10294790 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard message combined with action plans
Number of subjects: 0
Study 10294790 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus action plan message with wellness thinking information
Number of subjects: 0
Study 271585 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory agents
Number of subjects: 0
Study 31314925 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06648671
Number of subjects: 120
Study 31314925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30718126 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cytoreductive surgery (ICS) + hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 30718126 — intervention group
Group type: COMPARATOR
Intervention: Interval cytoreductive surgery (ICS)
Number of subjects: 0
Study 28282558 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+Nd:YAG laser
Number of subjects: 28
Study 28282558 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 28
Study 26066621 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar tissue sealer
Number of subjects: 32
Study 26066621 — intervention group
Group type: COMPARATOR
Intervention: Suture ligation (2/0 polyglactin sutures)
Number of subjects: 32
Study 23257667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Futures Oral Health curriculum
Number of subjects: 143
Study 22338921 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit box jumping exercise program
Number of subjects: 57
Study 19351801 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 12
Study 19351801 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine plus zolpidem (10 mg)
Number of subjects: 12
Study 19351801 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine plus trazodone (100 mg)
Number of subjects: 12
Study 19351801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16613915 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained patient educators (PEs)
Number of subjects: 50
Study 16613915 — intervention group
Group type: COMPARATOR
Intervention: Doctors
Number of subjects: 50
Study 15229817 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1 Mio KIE) administered at the latest 15 min before delivery
Number of subjects: 84
Study 15229817 — intervention group
Group type: COMPARATOR
Intervention: Normal deliveries without aprotinin
Number of subjects: 84
Study 15229817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean sections with aprotinin
Number of subjects: 84
Study 15229817 — intervention group
Group type: COMPARATOR
Intervention: Cesarean sections without aprotinin
Number of subjects: 84
Study 15229817 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII and partial thromboplastin time (PTT) in all study groups
Number of subjects: 84
Study 11505787 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinaceae purpureae herba (Echinacin, EC31J0)
Number of subjects: 80
Study 11505787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9289950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan prophylaxis
Number of subjects: 43
Study 9289950 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 43
Study 8515329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory/inpatient rotation
Number of subjects: 75
Study 8515329 — intervention group
Group type: COMPARATOR
Intervention: Exclusive inpatient training
Number of subjects: 75
Study 8515329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory training
Number of subjects: 75
Study 2952619 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin derivative (daily for 10 days)
Number of subjects: 32
Study 2952619 — intervention group
Group type: COMPARATOR
Intervention: Single dose of vasopressin derivative
Number of subjects: 32
Study 2952619 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin treatment (three times weekly for 6 weeks in rats)
Number of subjects: 32
Study 29373503 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular activity breaks (RAB) - 2 min of walking every 30 min
Number of subjects: 36
Study 29373503 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting (SIT)
Number of subjects: 36
Study 26821240 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine-medicated plasters
Number of subjects: 265
Study 25024650 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative Sleep Questionnaire (RSQ) administered to patients with primary insomnia assessed by polysomnography (PSG)
Number of subjects: 0
Study 25024650 — intervention group
Group type: COMPARATOR
Intervention: Restorative Sleep Questionnaire (RSQ) administered to healthy controls
Number of subjects: 0
Study 25024650 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative Sleep Questionnaire (RSQ) administered to subjects with NRS complaints
Number of subjects: 0
Study 22613634 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuvers (RMs)
Number of subjects: 0
Study 22613634 — intervention group
Group type: COMPARATOR
Intervention: 1 or fewer RMs
Number of subjects: 0
Study 22613634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 RMs
Number of subjects: 0
Study 22613634 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 3 RMs
Number of subjects: 0
Study 22613634 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapulmonary ALI
Number of subjects: 0
Study 20511208 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sumatriptan
Number of subjects: 749
Study 20511208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study 18806540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management based on clinical experience
Number of subjects: 0
Study 18806540 — intervention group
Group type: EXPERIMENTAL
Intervention: Current large-scale studies of pemphigus
Number of subjects: 0
Study 15647341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultradian blood pressure rhythms (12, 8, and 6 h)
Number of subjects: 214
Study 15647341 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian blood pressure rhythms
Number of subjects: 214
Study 15647341 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional BP dipping parameters (day/night difference, day/night ratio)
Number of subjects: 214
Study 15647341 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 214
Study 12532112 — intervention group
Group type: COMPARATOR
Intervention: Cat dander extract containing 0.6 microg Fel d 1
Number of subjects: 28
Study 12532112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat dander extract containing 3.0 microg Fel d 1
Number of subjects: 28
Study 12532112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat dander extract containing 15.0 microg Fel d 1
Number of subjects: 28
Study 12532112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10806258 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollerball endometrial ablation
Number of subjects: 255
Study 10806258 — intervention group
Group type: COMPARATOR
Intervention: Uterine balloon endometrial ablation
Number of subjects: 255
Study 10806258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures (rollerball and balloon)
Number of subjects: 255
Study 8649563 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 MIU rIFNbeta
Number of subjects: 34
Study 8649563 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 MIU rIFNbeta
Number of subjects: 34
Study 8649563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8649563 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFNbeta (unspecified dose)
Number of subjects: 34
Study 1517642 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50
Study 1517642 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 50
Study 6828559 — intervention group
Group type: EXPERIMENTAL
Intervention: Level side lying position with percussion
Number of subjects: 40
Study 6828559 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down side lying position with percussion
Number of subjects: 40
Study 6828559 — intervention group
Group type: COMPARATOR
Intervention: Level side lying position without percussion
Number of subjects: 40
Study 6828559 — intervention group
Group type: COMPARATOR
Intervention: Head-down side lying position without percussion
Number of subjects: 40
Study 31401049 — intervention group
Group type: COMPARATOR
Intervention: IV ketamine (7 mg kg‐1) and IV midazolam (0.25 mg kg‐1)
Number of subjects: 12
Study 31401049 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole (5 mg kg‐1) administered 12 and 24 hours prior to ketamine-midazolam
Number of subjects: 12
Study 29791970 — intervention group
Group type: EXPERIMENTAL
Intervention: HRC in hypoxia (HRChyp)
Number of subjects: 28
Study 29791970 — intervention group
Group type: COMPARATOR
Intervention: HRC in normoxia (HRCnorm)
Number of subjects: 28
Study 25098253 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone coaching and individualized web portal
Number of subjects: 118
Study 25098253 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study 24679401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant (expanded) nonverbal posture
Number of subjects: 81
Study 24679401 — intervention group
Group type: COMPARATOR
Intervention: Neutral nonverbal posture
Number of subjects: 81
Study 24679401 — intervention group
Group type: COMPARATOR
Intervention: Submissive (constricted) nonverbal posture
Number of subjects: 81
Study 22337532 — intervention group
Group type: EXPERIMENTAL
Intervention: VDW chemotherapy data for trastuzumab
Number of subjects: 400
Study 22337532 — intervention group
Group type: EXPERIMENTAL
Intervention: VDW chemotherapy data for anthracyclines
Number of subjects: 400
Study 22337532 — intervention group
Group type: EXPERIMENTAL
Intervention: VDW chemotherapy data for other chemotherapy
Number of subjects: 400
Study 22337532 — intervention group
Group type: EXPERIMENTAL
Intervention: VDW mean doses for trastuzumab
Number of subjects: 400
Study 22337532 — intervention group
Group type: EXPERIMENTAL
Intervention: VDW mean doses for anthracyclines
Number of subjects: 400
Study 19818174 — intervention group
Group type: EXPERIMENTAL
Intervention: Coartem Dispersible (dispersible formulation of artemether/lumefantrine)
Number of subjects: 899
Study 19818174 — intervention group
Group type: COMPARATOR
Intervention: Crushed AL tablets (control)
Number of subjects: 899
Study 17973730 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promotion Health Center (HPHC) programs
Number of subjects: 2261
Study 17973730 — intervention group
Group type: COMPARATOR
Intervention: Non-HPHC sites (Control)
Number of subjects: 2261
Study 15310739 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg Cr picolinate
Number of subjects: 13
Study 15310739 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg Cr picolinate
Number of subjects: 13
Study 15310739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11555446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length assessment
Number of subjects: 6334
Study 11555446 — intervention group
Group type: EXPERIMENTAL
Intervention: Funneling of the internal os
Number of subjects: 6334
Study 11555446 — intervention group
Group type: COMPARATOR
Intervention: Cervical length and funneling
Number of subjects: 6334
Study 9750527 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy for 2 years
Number of subjects: 176
Study 9750527 — intervention group
Group type: COMPARATOR
Intervention: Control (immediate surgery)
Number of subjects: 176
Study 9750527 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy for 2 years (stage C cancer)
Number of subjects: 176
Study 9750527 — intervention group
Group type: COMPARATOR
Intervention: Control (immediate surgery, stage C cancer)
Number of subjects: 176
Study 7825970 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of 5FU based on pharmacokinetic information
Number of subjects: 38
Study 7825970 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of 5FU
Number of subjects: 38
Study 3339175 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter (11F diameter, tripolar, distal platinum‐iridium tip for pacing, middle 4.3 cm2 platinum electrode at right ventricular apex, proximal 8.5 cm2 platinum electrode at superior vena cava-right atrial junction)
Number of subjects: 15
Study 3339175 — intervention group
Group type: COMPARATOR
Intervention: Superior vena cava spring-left ventricular patch electrode system (6.7 cm2 anode, 13.5 cm2 cathode)
Number of subjects: 15
Study 3339175 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter
Number of subjects: 15
Study 3339175 — intervention group
Group type: COMPARATOR
Intervention: Spring-patch system
Number of subjects: 15
Study 29550013 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue (REC Blue; VDW, Munich, Germany)
Number of subjects: 60
Study 29550013 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFlex EDM (HEDM; Coltene/Whaledent, Altstätten, Switzerland)
Number of subjects: 60
Study 29550013 — intervention group
Group type: EXPERIMENTAL
Intervention: XP‐endo Shaper (XPS; FKG Dentaire SA, La Chaux‐de‐Fonds, Switzerland)
Number of subjects: 60
Study 27716446 — intervention group
Group type: EXPERIMENTAL
Intervention: MFES-assisted gait training
Number of subjects: 40
Study 27716446 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 40
Study 24872563 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based channel tuning functions (CTFs) during the orientation WM task
Number of subjects: 0
Study 24872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsample cue to store or drop the memorandum
Number of subjects: 0
Study 24872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to store one of two simultaneously presented stimuli
Number of subjects: 0
Study 23025129 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch with Guided Imagery (HT+GI)
Number of subjects: 123
Study 23025129 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 123
Study 20203627 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day of flavanol-rich dark chocolate
Number of subjects: 102
Study 20203627 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g/day of flavanol-rich dark chocolate
Number of subjects: 102
Study 18752690 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine/CBT
Number of subjects: 31
Study 18752690 — intervention group
Group type: COMPARATOR
Intervention: placebo/CBT
Number of subjects: 31
Study 16521846 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% CHO + 2% protein (CHO-P)
Number of subjects: 8
Study 16521846 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO (CHO6)
Number of subjects: 8
Study 16521846 — intervention group
Group type: COMPARATOR
Intervention: 10% CHO (CHO10)
Number of subjects: 8
Study 16521846 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 km time trial
Number of subjects: 8
Study 12004845 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 3118
Study 12004845 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant chemotherapy)
Number of subjects: 3118
Study 10326149 — intervention group
Group type: EXPERIMENTAL
Intervention: New thrombolytic agents (including reteplase, TNK-t-PA, lanoteplase)
Number of subjects: 0
Study 10326149 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytics combined with new glycoprotein IIb/IIIa platelet inhibitors and anti-thrombin agents
Number of subjects: 0
Study 10326149 — intervention group
Group type: COMPARATOR
Intervention: Current thrombolytics
Number of subjects: 0
Study 8941528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench-press training with heavy loads
Number of subjects: 40
Study 8941528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench-press training with light loads
Number of subjects: 40
Study 8941528 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative training group using different exercises
Number of subjects: 40
Study 8941528 — intervention group
Group type: COMPARATOR
Intervention: Control group that did not train
Number of subjects: 40
Study 1828659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day (treatment A)
Number of subjects: 16
Study 1828659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 1.25 mg/day (treatment B)
Number of subjects: 16
Study 6940466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction chemotherapy (TAD) consisting of 6-thioguanine, cytarabine, and daunorubicin
Number of subjects: 68
Study 6940466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation chemotherapy followed by maintenance chemotherapy with immunotherapy
Number of subjects: 68
Study 6940466 — intervention group
Group type: COMPARATOR
Intervention: Intensive consolidation chemotherapy followed by maintenance chemotherapy without immunotherapy
Number of subjects: 68
Study 31862620 — intervention group
Group type: EXPERIMENTAL
Intervention: High screen time (HST, ST > 6 h/day)
Number of subjects: 1137
Study 31862620 — intervention group
Group type: EXPERIMENTAL
Intervention: Light- and moderate-intensity physical activity (LMPA)
Number of subjects: 1137
Study 31862620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low screen time (LST) and light- and moderate-intensity physical activity (LMPA)
Number of subjects: 1137
Study 31862620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high screen time (HST) and vigorous-intensity physical activity (VIPA)
Number of subjects: 1137
Study 31862620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high screen time (HST) and light- and moderate-intensity physical activity (LMPA)
Number of subjects: 1137
Study 31775859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal lactic acid gel 5 ml once daily for 7 days
Number of subjects: 1900
Study 31775859 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole tablets 400 mg twice daily for 7 days
Number of subjects: 1900
Study 28287054 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 45 minutes once a week
Number of subjects: 0
Study 28287054 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 15 minutes three times a week (total 45 minutes per week)
Number of subjects: 0